H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $34 from $36 and keeps a Buy rating on the shares following the Q4 results.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- RegenXBio’s Strategic Advancements and Financial Stability Highlighted in Analyst Recommendation
- REGENXBIO Earnings Call Highlights Strategic Progress
- Regenxbio price target raised to $24 from $22 at Morgan Stanley
- RegenXBio: Strong Buy Rating Backed by Clinical Progress and Solid Financial Position
- REGENXBIO Reports Progress in Gene Therapy Pipeline